Share to:

 

Peripheral tolerance

In immunology, peripheral tolerance is the second branch of immunological tolerance, after central tolerance. It takes place in the immune periphery (after T and B cells egress from primary lymphoid organs). Its main purpose is to ensure that self-reactive T and B cells which escaped central tolerance do not cause autoimmune disease.[1] Peripheral tolerance can also serve a purpose in preventing an immune response to harmless food antigens and allergens.[2]

Self reactive cells are subject to clonal deletion or clonal diversion. Both processes of peripheral tolerance control the presence and production of self reactive immune cells.[3] Deletion of self-reactive T cells in the thymus is only 60-70% efficient, and naive T cell repertoire contains a significant portion of low-avidity self-reactive T cells. These cells can trigger an autoimmune response, and there are several mechanisms of peripheral tolerance to prevent their activation.[4] Antigen-specific mechanisms of peripheral tolerance include persistent of T cell in quiescence, ignorance of antigen and direct inactivation of effector T cells by either clonal deletion, conversion to regulatory T cells (Tregs) or induction of anergy.[5][4] Tregs, which are also generated during thymic T cell development, further suppress the effector functions of conventional lymphocytes in the periphery.[6] Dendritic cells (DCs) participate in the negative selection of autoreactive T cells in the thymus, but they also mediate peripheral immune tolerance through several mechanisms.[7]

Dependence of a particular antigen on either central or peripheral tolerance is determined by its abundance in the organism.[8] B Cells have a lower probability that they will express cell surface markers to pose the threat of causing an autoimmune attack.[9] Peripheral tolerance of B cells is largely mediated by B cell dependence on T cell help. However, B cell peripheral tolerance is much less studied.

Cells mediating peripheral tolerance

Regulatory T cells

Tregs are the central mediators of immune suppression and they play a key role in maintaining peripheral tolerance. The master regulator of Treg phenotype and function is Foxp3. Natural Tregs (nTregs) are generated in the thymus during the negative selection. TCR of nTregs shows a high affinity for self-peptides, Induced Tregs (iTreg) develop from conventional naive helper T cells after antigen recognition in presence of TGF-β and IL-2. iTregs are enriched in the gut to establish tolerance to commensal microbiota and harmless food antigens.[10] Regardless of their origin, once present Tregs use several different mechanisms to suppress autoimmune reactions. These include depletion of IL-2 from the environment, secretion of anti-inflammatory cytokines IL-10, TGF-β and IL-35[11] and induction of apoptosis of effector cells. CTLA-4 is a surface molecule present on Tregs which can prevent CD28 mediated costimulation of T cells after TCR antigen recognition.[6]  

Tolerogenic DCs

DCs are a major cell population responsible for the initiation of the adaptive immune response. They present short peptides on MHCII, which are recognized by specific TCR. After encountering an antigen with recognition danger or pathogen-associated molecular patterns, DCs start the secretion of proinflammatory cytokines, express costimulatory molecules CD80 and CD86 and migrate to the lymph nodes to activate naive T cells. [1] However, immature DCs (iDCs) are able to induce both CD4 and CD8 tolerance. The immunogenic potential of iDCs is weak, because of the low expression of costimulatory molecules and a modest level of MHCII. iDCs perform endocytosis and phagocytosis of foreign antigens and apoptotic cells, which occurs physiologically in peripheral tissues. Antigen-loaded iDCs migrate to the lymph nodes, secrete IL-10, TGF-β and present antigen to the naive T cells without costimulation. If the T cell recognizes the antigen, it is turned into the anergic state, depleted or converted to Treg.[12] iDCs are more potent Treg inducers than lymph node resident DCs.[7] BTLA is a crucial molecule for DCs mediated Treg conversion.[13] Tolerogenic DCs express FasL and TRAIL to directly induce apoptosis of responding T cells. They also produce indoleamine 2,3-dioxygenase (IDO) to prevent T cell proliferation. Retinoic acid is secreted to support iTreg differentiation, too.[14] Nonetheless, upon maturation (for example during the infection) DCs largely lose their tolerogenic capabilities.[12]

LNSCs

Aside from dendritic cells, additional cell populations were identified that are able to induce antigen-specific T cell tolerance. These are mainly the members of lymph node stromal cells (LNSCs). LNSCs are generally divided into several subpopulations based on the expression of gp38 (PDPN) and CD31 surface markers.[15] Among those, only fibroblastic reticular cells and lymphatic endothelial cells (LECs) were shown to play a role in peripheral tolerance. Both of those populations are able to induce CD8 T cell tolerance by the presentation of the endogenous antigens on MHCI molecules.[16][17] LNSCs lack expression of the autoimmune regulator, and the production of autoantigens depends on transcription factor Deaf1. LECs express PD-L1 to engage PD-1 on CD8 T cells to restrict self-reactivity.[18] LNSCs can drive the CD4 T cell tolerance by the presentation of the peptide-MHCII complexes, which they acquired from the DCs.[19] On the other hand, LECs can serve as a self-antigen reservoir and can transport self-antigens to DCs to direct self-peptide-MHCII presentation to CD4 T cells. In mesenteric lymph nodes(mLN), LNSCs can induce Tregs directly by secretion of TGF-β or indirectly by imprinting mLN-resident DCs.[18]

Intrinsic mechanisms of T cell peripheral tolerance

Although the majority of self-reactive T cell clones are deleted in the thymus by the mechanisms of central tolerance, low affinity self-reactive T cells continuously escape to the immune periphery.[8] Therefore, additional mechanisms exist to prevent self-reactive and unrestained T cells responses.

Quiescence

When naive T cells exit the thymus, they are in a quiescent state. That means they are in the non-proliferative, G0 stage of the cell cycle and they have low metabolic, transcriptional and translational activities, but still retain the capacity to enter the cell cycle.[20] Quiescence can prevent naive T cell activation after tonic signaling, meaning that T cells may be constitutively activated when not in the presence of a ligand.[21] After antigen exposure and costimulation, naive T cells start the process called quiescence exit, which results in proliferation and effector differentiation.[22]

Naive cells must enter and exit a quiescent state at the proper timing in their life cycle. If T cells exit a quiescence prematurely there is a lack of tolerance to potential self-reactive cells. T cells rely on negative regulators to keep them in a quiescence state until they are ready for exit, the down regulation of negative regulators increases T cell activation. Premature and over activation of T cells can lead to harmful down stream responses and possibly trigger an autoimmune response.[23]

As cells exit a quiescent state they will up regulate enzymes that are responsible for production of essential pathways (nucleic acids, proteins, carbohydrates, etc.).[23] At this stage the T cell will enter the cell cycle and continue to be metabolically active.

Ignorance

When self-reactive T cells escape thymic deletion they may enter an ignorant state.[24] Self-reactive T cells can fail to initiate immune response after recognition of self-antigen. These T cells are not classified as dysfunctional members of the immune response, rather they are antigen-inexperienced naive cells that will remain in circulation.[25] These cells remain the ability to become activated if in the presence of the correct stimuli.

Ignorance can be seen in situations where there is not a high enough concentration of antigen to trigger activation. The intrinsic mechanism of ignorance is when the affinity of TCR to antigen is too low to elicit T cell activation. There is also an extrinsic mechanism. Antigens, which are present in generally low numbers, can´t stimulate T cells sufficiently.[1] Additionally, there are anatomical barriers that prohibit the activation of these T cells. These specialized mechanisms ensuring ignorance by the immune system have developed in so-called immune privileged organs.[5]

T cells can overcome ignorance through a sufficient signal from signaling molecules (cytokines, infection, inflammatory stimuli, etc.) and induce an autoimmune response.[25] In the inflammatory context, T cells can override ignorance and induce autoimmune disease.[4]

Anergy

Anergy is a state of functional unresponsiveness induced upon self antigen recognition.[26] T-cells can be made non-responsive to antigens presented if the T-cell engages an MHC molecule on an antigen presenting cell (signal 1) without engagement of costimulatory molecules (signal 2). Co-stimulatory molecules are upregulated by cytokines (signal 3) in the context of acute inflammation. Without pro-inflammatory cytokines, co-stimulatory molecules will not be expressed on the surface of the antigen presenting cell, and so anergy will result if there is an MHC-TCR interaction between the T cell and the APC.[5]  TCR stimulation leads to translocation of NFAT into the nucleus. In the absence of costimulation, there is no MAPK signaling in T cells and translocation of transcription factor AP-1 into the nucleus is impaired. This disbalance of transcription factors in T cells results in the expression of several genes involved in forming an anergic state.[27]  Anergic T cells show long-lasting epigenetic programming that silences effector cytokine production. Anergy is reversible and T cells can recover their functional responsiveness in the absence of the antigen.[4]  

Peripheral deletion

Before release into the periphery T cells are subjected to thymic deletion if they prove to have the capacity to react with self. Peripheral deletion is the disposal of potential self reactive T cells that escaped thymic deletion.[28]

After T cell response to co-stimulation-deficient antigen, a minor population of T cells develop anergy and a large proportion of T cells are rapidly lost by apoptosis. This cell death can be mediated by intrinsic pro-apoptotic family member BIM. The balance between proapoptotic BIM and the antiapoptotic mediator BCL-2 determine the eventual fate of the tolerized T cell.[4]  There are also extrinsic mechanisms of deletion mediated by the cytotoxic activity of Fas/FasL or TRAIL/TRAILR interaction.[14] Cell death can be mediated by intrinsic of extrinsic methods as mentioned. In most instances there is an up regulation of death markers or the presence of Bcl-2 proteins, which are proteins that are essential in facilitating programmed cell death.[28]

Immunoprivileged organs

Immunopriviledged organs evolved mechanisms in which specialized tissue cells and immune cells can mount an appropriate response without disturbing the specialized tissue.[29] Immunopathogenic disturbances are not present in a variety of specialized organs such as; the eyes, reproductive organs and the central nervous system. These areas are protected by several mechanisms: Fas-ligand expression binds Fas on lymphocytes inducing apoptosis, anti-inflammatory cytokines (including TGF-beta and interleukin 10) and blood-tissue-barrier with tight junctions between endothelial cells.

Split tolerance

Split tolerance describes how some antigens can trigger an immune response in one aspect of the immune system and the same antigen could not trigger a response in another set of immune cells. Since many pathways of immunity are interdependent, they do not all need to be tolerized. For example, tolerized T cells will not activate auto-reactive B cells. Without this help from CD4 T cells, the B cells will not be activated.[1]

References

  1. ^ a b c d Janeway, Charles (2001-01-01). Immunobiology Five. Garland Pub. ISBN 9780815336426.
  2. ^ Soyer, O. U.; Akdis, M.; Ring, J.; Behrendt, H.; Crameri, R.; Lauener, R.; Akdis, C. A. (2013). "Mechanisms of peripheral tolerance to allergens". Allergy. 68 (2): 161–170. doi:10.1111/all.12085. ISSN 1398-9995. PMID 23253293. S2CID 24008758.
  3. ^ Xing, Yan; Hogquist, Kristin A. (June 2012). "T-Cell Tolerance: Central and Peripheral". Cold Spring Harbor Perspectives in Biology. 4 (6): a006957. doi:10.1101/cshperspect.a006957. ISSN 1943-0264. PMC 3367546. PMID 22661634.
  4. ^ a b c d e ElTanbouly, Mohamed A.; Noelle, Randolph J. (April 2021). "Rethinking peripheral T cell tolerance: checkpoints across a T cell's journey". Nature Reviews Immunology. 21 (4): 257–267. doi:10.1038/s41577-020-00454-2. ISSN 1474-1741. PMID 33077935. S2CID 224808870.
  5. ^ a b c Mueller, Daniel L (2010). "Mechanisms maintaining peripheral tolerance". Nature Immunology. 11 (1): 21–27. doi:10.1038/ni.1817. PMID 20016506. S2CID 9612138.
  6. ^ a b Cretney, Erika; Kallies, Axel; Nutt, Stephen L. (2013). "Differentiation and function of Foxp3+ effector regulatory T cells". Trends in Immunology. 34 (2): 74–80. doi:10.1016/j.it.2012.11.002. PMID 23219401.
  7. ^ a b Hasegawa, Hitoshi; Matsumoto, Takuya (2018). "Mechanisms of Tolerance Induction by Dendritic Cells In Vivo". Frontiers in Immunology. 9: 350. doi:10.3389/fimmu.2018.00350. ISSN 1664-3224. PMC 5834484. PMID 29535726.
  8. ^ a b Malhotra, Deepali; Linehan, Jonathan L; Dileepan, Thamotharampillai; Lee, You Jeong; Purtha, Whitney E; Lu, Jennifer V; Nelson, Ryan W; Fife, Brian T; Orr, Harry T; Anderson, Mark S; Hogquist, Kristin A; Jenkins, Marc K (2016). "Tolerance is established in polyclonal CD4+ T cells by distinct mechanisms, according to self-peptide expression patterns". Nature Immunology. 17 (2): 187–195. doi:10.1038/ni.3327. PMC 4718891. PMID 26726812.
  9. ^ Getahun, Andrew (May 2022). "The role of inhibitory signaling in peripheral B cell tolerance". Immunological Reviews. 307 (1): 27–42. doi:10.1111/imr.13070. ISSN 0105-2896. PMC 8986582. PMID 35128676.
  10. ^ Kanamori, Mitsuhiro; Nakatsukasa, Hiroko; Okada, Masahiro; Lu, Qianjin; Yoshimura, Akihiko (2016-11-01). "Induced Regulatory T Cells: Their Development, Stability, and Applications". Trends in Immunology. 37 (11): 803–811. doi:10.1016/j.it.2016.08.012. ISSN 1471-4906. PMID 27623114.
  11. ^ Dominguez-Villar, Margarita; Hafler, David A. (July 2018). "Regulatory T cells in autoimmune disease". Nature Immunology. 19 (7): 665–673. doi:10.1038/s41590-018-0120-4. ISSN 1529-2916. PMC 7882196. PMID 29925983.
  12. ^ a b Steinman, Ralph M.; Hawiger, Daniel; Nussenzweig, Michel C. (2003-04-01). "Tolerogenic dendritic cells". Annual Review of Immunology. 21 (1): 685–711. doi:10.1146/annurev.immunol.21.120601.141040. ISSN 0732-0582. PMID 12615891.
  13. ^ Jones, Andrew; Bourque, Jessica; Kuehm, Lindsey; Opejin, Adeleye; Teague, Ryan M.; Gross, Cindy; Hawiger, Daniel (2016). "Immunomodulatory Functions of BTLA and HVEM Govern Induction of Extrathymic Regulatory T Cells and Tolerance by Dendritic Cells". Immunity. 45 (5): 1066–1077. doi:10.1016/j.immuni.2016.10.008. PMC 5112132. PMID 27793593.
  14. ^ a b Domogalla, Matthias P.; Rostan, Patricia V.; Raker, Verena K.; Steinbrink, Kerstin (2017). "Tolerance through Education: How Tolerogenic Dendritic Cells Shape Immunity". Frontiers in Immunology. 8: 1764. doi:10.3389/fimmu.2017.01764. ISSN 1664-3224. PMC 5770648. PMID 29375543.
  15. ^ Koning, Jasper J.; Mebius, Reina E. (2012). "Interdependence of stromal and immune cells for lymph node function". Trends in Immunology. 33 (6): 264–270. doi:10.1016/j.it.2011.10.006. PMID 22153930.
  16. ^ Fletcher, Anne L.; Lukacs-Kornek, Veronika; Reynoso, Erika D.; Pinner, Sophie E.; Bellemare-Pelletier, Angelique; Curry, Mark S.; Collier, Ai-Ris; Boyd, Richard L.; Turley, Shannon J. (2010-04-12). "Lymph node fibroblastic reticular cells directly present peripheral tissue antigen under steady-state and inflammatory conditions". Journal of Experimental Medicine. 207 (4): 689–697. doi:10.1084/jem.20092642. ISSN 0022-1007. PMC 2856033. PMID 20308362.
  17. ^ Cohen, Jarish N.; Guidi, Cynthia J.; Tewalt, Eric F.; Qiao, Hui; Rouhani, Sherin J.; Ruddell, Alanna; Farr, Andrew G.; Tung, Kenneth S.; Engelhard, Victor H. (2010-04-12). "Lymph node–resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation". Journal of Experimental Medicine. 207 (4): 681–688. doi:10.1084/jem.20092465. ISSN 0022-1007. PMC 2856027. PMID 20308365.
  18. ^ a b Krishnamurty, Akshay T.; Turley, Shannon J. (April 2020). "Lymph node stromal cells: cartographers of the immune system". Nature Immunology. 21 (4): 369–380. doi:10.1038/s41590-020-0635-3. ISSN 1529-2916. PMID 32205888. S2CID 214618784.
  19. ^ Dubrot, Juan; Duraes, Fernanda V.; Potin, Lambert; Capotosti, Francesca; Brighouse, Dale; Suter, Tobias; LeibundGut-Landmann, Salomé; Garbi, Natalio; Reith, Walter (2014-06-02). "Lymph node stromal cells acquire peptide–MHCII complexes from dendritic cells and induce antigen-specific CD4+ T cell tolerance". Journal of Experimental Medicine. 211 (6): 1153–1166. doi:10.1084/jem.20132000. ISSN 0022-1007. PMC 4042642. PMID 24842370.
  20. ^ Urbán, Noelia; Cheung, Tom H. (2021-02-01). "Stem cell quiescence: the challenging path to activation". Development. 148 (3): dev165084. doi:10.1242/dev.165084. ISSN 0950-1991. PMC 7888710. PMID 33558315.
  21. ^ Ajina, Adam; Maher, John (2018-09-01). "Strategies to Address Chimeric Antigen Receptor Tonic Signaling". Molecular Cancer Therapeutics. 17 (9): 1795–1815. doi:10.1158/1535-7163.mct-17-1097. ISSN 1535-7163. PMC 6130819. PMID 30181329.
  22. ^ Chapman, Nicole M.; Boothby, Mark R.; Chi, Hongbo (January 2020). "Metabolic coordination of T cell quiescence and activation". Nature Reviews Immunology. 20 (1): 55–70. doi:10.1038/s41577-019-0203-y. ISSN 1474-1741. PMID 31406325. S2CID 199542651.
  23. ^ a b Marescal, Océane; Cheeseman, Iain M. (November 2020). "Cellular Mechanisms and Regulation of Quiescence". Developmental Cell. 55 (3): 259–271. doi:10.1016/j.devcel.2020.09.029. hdl:1721.1/138195.2. PMC 7665062. PMID 33171109.
  24. ^ Parish, Ian A; Heath, William R (February 2008). "Too dangerous to ignore: self-tolerance and the control of ignorant autoreactive T cells". Immunology & Cell Biology. 86 (2): 146–152. doi:10.1038/sj.icb.7100161. ISSN 0818-9641.
  25. ^ a b Schietinger, Andrea; Greenberg, Philip D. (February 2014). "Tolerance and exhaustion: defining mechanisms of T cell dysfunction". Trends in Immunology. 35 (2): 51–60. doi:10.1016/j.it.2013.10.001. PMC 3946600. PMID 24210163.
  26. ^ Kalekar, Lokesh A.; Mueller, Daniel L. (2017-04-01). "Relationship between CD4 Tregs and anergy in vivo". Journal of Immunology. 198 (7): 2527–2533. doi:10.4049/jimmunol.1602031. ISSN 0022-1767. PMC 5363282. PMID 28320913.
  27. ^ Macián, Fernando; Garcı́a-Cózar, Francisco; Im, Sin-Hyeog; Horton, Heidi F.; Byrne, Michael C.; Rao, Anjana (2002-06-14). "Transcriptional Mechanisms Underlying Lymphocyte Tolerance". Cell. 109 (6): 719–731. doi:10.1016/S0092-8674(02)00767-5. ISSN 0092-8674. PMID 12086671. S2CID 15599878.
  28. ^ a b Herndon, John M.; Stuart, Patrick M.; Ferguson, Thomas A. (2005-04-01). "Peripheral Deletion of Antigen-Specific T Cells Leads to Long-Term Tolerance Mediated by CD8+ Cytotoxic Cells". The Journal of Immunology. 174 (7): 4098–4104. doi:10.4049/jimmunol.174.7.4098. ISSN 0022-1767.
  29. ^ Streilein, J. Wayne; Takeuchi, Masaharu; Taylor, Andrew W. (February 1997). "Immune privilege, T-cell tolerance, and tissue-restricted autoimmunity". Human Immunology. 52 (2): 138–143. doi:10.1016/S0198-8859(96)00288-1. PMID 9077562.
Kembali kehalaman sebelumnya